Lab firm CEO retires, to be replaced by former AstraZeneca exec

FORT MYERS — Douglas VanOort, longtime CEO of oncology testing and global contract research services firm NeoGenomics, has announced his retirement from the CEO role, transitioning to executive chairman.

Mark Mallon, a former executive vice president of AstraZeneca and most recently the CEO of Cambridge, Mass.-based Ironwood Pharmaceuticals, was named CEO. The new positions, part of a deliberate succession planning process, go into effect April 19, according to a statement. Mallon will also join the board of NeoGenomics, a publicly traded company. The company, traded on the Nasdaq (symbol: NEO) posted $444.5 million in revenue in 2020.